MVA-member Clinical Microbiomics and CosmosID will form the first-ever microbiome service company with a global infrastructure of state-of-the-art multi-omics laboratories, advanced bioinformatics, applied AI and integrative systems biology expertise meeting GxP Standards.
The purpose of the new company is to help scientists worldwide understand how the microbiome influences health and well-being– from humans and animals to plants and the environment.
Anders Grøn, CEO at Clinical Microbiomics, commented:
“We are a company made up of scientists – Innovation is at the heart of our DNA. With this merger, we pool our expertise, resources, and commitment to pushing the boundaries of what’s possible in microbiome research. Our aim is clear: to enable and empower microbiome scientists with new tools, concepts and insights that will catalyze groundbreaking discoveries. Microbiome is the next modality in healthcare, and we’re here to help our clients and partners lead the way.”
Learn more and read the full press release